List view / Grid view
New findings support use of salbutamol MDI formulation in the next-generation low carbon propellant as a more sustainable option for patients with respiratory disease.
The move will boost its oncology pipeline, adding a potential first-in-class anti-BTN3A monoclonal antibody for acute myeloid leukaemia.
Merck & Co’s anti-PD-1 immunotherapy showed evidence at ESMO of its ability to prevent cancer recurrence in Merkel cell carcinoma.
Establishes Resource for AI Science in Europe and eyes frontier AI models and autonomous agentic AI for pharma.
![Close up view of the Merck logo on the top corner of a glass building [Credit: Michael Vi / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Merck-aquisition-300x278.jpg)
![Close up view of the Merck logo on the top corner of a glass building [Credit: Michael Vi / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Merck-aquisition-scaled-e1605009301887.jpg)
The study is one of three to start, along with those in hidradenitis suppurativa and radiographic axial spondyloarthritis.
Offers potential symptomatic relief for cancer patients with chemotherapy-induced peripheral neuropathy (CIPN).
Companies’ first-line ambitions for the antibody drug conjugate buoyed by the TROPION-Breast02 clinical trial.
The company will instead focus its attention on advancing candidates for modalities that include biologics and ADCs.
Despite progress from AstraZeneca, Sanofi, Merck & Co, GSK and Pfizer, analysts say effective respiratory syncytial virus treatments are still needed.
The US FDA approvals make the drug the first IL-23 inhibitor to be licensed for two common skin conditions.
uniQure’s positive topline data “are the most convincing in the field to date” and indicate the gene therapy’s potential disease-modifying effects.
Advances cell therapy and gene therapy candidates, with both showing neurorestorative potential against the disease.
EPR Issue 3 includes articles on microbiology, downstream processing, manufacturing, drug formulation and more.
Winners of this year's awards will be revealed during the opening of CPHI Frankfurt 2025.
The innovation is set to change how eligible bladder cancer patients in the US are treated who are unresponsive to traditional therapy.
